RT Conference Proceedings T1 Efficacy and safety evaluation of nilotinib and dasatinib (2G -TKI) on first line treatment in 73 patients with CML-CP outside of clinical trials. Andalusian CML registry (RALMC) A1 Puerta, JM A1 Jiménez Velasco, A A1 García, MJ A1 Molina, JR A1 Ruiz, C A1 Ferrer, C A1 Durán, MS A1 Simón, I A1 Clavero, E A1 Avellaneda, MC A1 Rosell, A A1 Ballesteros, I A1 Ramírez, S A1 Portero, MA A1 Ramírez, MJ A1 Fernández, M A1 Jiménez, M A1 Fe, R A1 Mulero, N A1 López, P K1 Dasatinib K1 Humanos K1 Mesilato de imatinib K1 Leucemia mielogenosa crónica BCR-ABL positiva K1 Pirimidinas K1 Sistema de registros K1 Andalucía AB Even though they were approved last June 2011 to be used on first line, it is not a common procedure to begin treatment of CML-CP with 2GTKI, despite it has been demonstrated its efficacy and safety against imatinibon ENESTnd and Dasision clinical trials. PB Ferrata Storti Foundation SN 0390-6078 YR 2016 FD 2016-06 LK http://hdl.handle.net/10668/2445 UL http://hdl.handle.net/10668/2445 LA en NO Puerta JM, Jiménez Velasco A, García MJ, Molina JR, Ruiz C, Ferrer C, et al.Efficacy and safety evaluation of nilotinib and dasatinib (2G -TKI) on first line treatment in 73 patients with CML-CP outside of clinical trials. Andalusian CML registry (RALMC). Haematologica. 2016; 101(s1).PB1820 DS RISalud RD Mar 18, 2025